Preliminary data suggestive of a novel translational approach to mesothelioma treatment: Imatinib mesylate with gemcitabine or pemetrexed

Pietro Bertino, Camillo Porta, Dario Barbone, Serena Germano, Sara Busacca, Sabrina Pinato, Giancarlo Tassi, Roberto Favoni, Giovanni Gaudino, Luciano Mutti

Research output: Contribution to journalArticle

Abstract

Background: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet derived growth factor receptor β (PDGFRβ). PDGFRβ is often overexpressed in mesothelioma cells and is a therapeutic target for imatinib in some solid tumours. A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma. Methods: Cultures from mesothelioma MMP, REN ana ISTMES2 cell lines were treated with imatinib alone or in combination with a chemotherapeutic agent. Results: Imatinib induced cytotoxicity and apoptosis selectively on PDGFRp positive mesothelioma cells via blockade of receptor phosphorylation and interference with the Akt pathway. Of the chemotherapeutic agents tested in combination with imatinib, a synergistic effect was obtained with gemcitabine and pemetrexed. Conclusions: This study provides a rationale for a novel translational approach to the treatment of mesothelioma which relies on enhancement of tumour chemosensitivity by inhibition of Akt.

Original languageEnglish
Pages (from-to)690-695
Number of pages6
JournalThorax
Volume62
Issue number8
DOIs
Publication statusPublished - Aug 2007

Fingerprint

gemcitabine
Pemetrexed
Mesothelioma
Platelet-Derived Growth Factor Receptors
Neoplasms
Matrix Metalloproteinases
Protein-Tyrosine Kinases
Imatinib Mesylate
Phosphorylation
Apoptosis
Cell Line

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Preliminary data suggestive of a novel translational approach to mesothelioma treatment : Imatinib mesylate with gemcitabine or pemetrexed. / Bertino, Pietro; Porta, Camillo; Barbone, Dario; Germano, Serena; Busacca, Sara; Pinato, Sabrina; Tassi, Giancarlo; Favoni, Roberto; Gaudino, Giovanni; Mutti, Luciano.

In: Thorax, Vol. 62, No. 8, 08.2007, p. 690-695.

Research output: Contribution to journalArticle

Bertino, P, Porta, C, Barbone, D, Germano, S, Busacca, S, Pinato, S, Tassi, G, Favoni, R, Gaudino, G & Mutti, L 2007, 'Preliminary data suggestive of a novel translational approach to mesothelioma treatment: Imatinib mesylate with gemcitabine or pemetrexed', Thorax, vol. 62, no. 8, pp. 690-695. https://doi.org/10.1136/thx.2006.069872
Bertino, Pietro ; Porta, Camillo ; Barbone, Dario ; Germano, Serena ; Busacca, Sara ; Pinato, Sabrina ; Tassi, Giancarlo ; Favoni, Roberto ; Gaudino, Giovanni ; Mutti, Luciano. / Preliminary data suggestive of a novel translational approach to mesothelioma treatment : Imatinib mesylate with gemcitabine or pemetrexed. In: Thorax. 2007 ; Vol. 62, No. 8. pp. 690-695.
@article{8c8238b5303b4daca1de0e3ad535cd84,
title = "Preliminary data suggestive of a novel translational approach to mesothelioma treatment: Imatinib mesylate with gemcitabine or pemetrexed",
abstract = "Background: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet derived growth factor receptor β (PDGFRβ). PDGFRβ is often overexpressed in mesothelioma cells and is a therapeutic target for imatinib in some solid tumours. A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma. Methods: Cultures from mesothelioma MMP, REN ana ISTMES2 cell lines were treated with imatinib alone or in combination with a chemotherapeutic agent. Results: Imatinib induced cytotoxicity and apoptosis selectively on PDGFRp positive mesothelioma cells via blockade of receptor phosphorylation and interference with the Akt pathway. Of the chemotherapeutic agents tested in combination with imatinib, a synergistic effect was obtained with gemcitabine and pemetrexed. Conclusions: This study provides a rationale for a novel translational approach to the treatment of mesothelioma which relies on enhancement of tumour chemosensitivity by inhibition of Akt.",
author = "Pietro Bertino and Camillo Porta and Dario Barbone and Serena Germano and Sara Busacca and Sabrina Pinato and Giancarlo Tassi and Roberto Favoni and Giovanni Gaudino and Luciano Mutti",
year = "2007",
month = "8",
doi = "10.1136/thx.2006.069872",
language = "English",
volume = "62",
pages = "690--695",
journal = "Thorax",
issn = "0040-6376",
publisher = "BMJ Publishing Group",
number = "8",

}

TY - JOUR

T1 - Preliminary data suggestive of a novel translational approach to mesothelioma treatment

T2 - Imatinib mesylate with gemcitabine or pemetrexed

AU - Bertino, Pietro

AU - Porta, Camillo

AU - Barbone, Dario

AU - Germano, Serena

AU - Busacca, Sara

AU - Pinato, Sabrina

AU - Tassi, Giancarlo

AU - Favoni, Roberto

AU - Gaudino, Giovanni

AU - Mutti, Luciano

PY - 2007/8

Y1 - 2007/8

N2 - Background: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet derived growth factor receptor β (PDGFRβ). PDGFRβ is often overexpressed in mesothelioma cells and is a therapeutic target for imatinib in some solid tumours. A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma. Methods: Cultures from mesothelioma MMP, REN ana ISTMES2 cell lines were treated with imatinib alone or in combination with a chemotherapeutic agent. Results: Imatinib induced cytotoxicity and apoptosis selectively on PDGFRp positive mesothelioma cells via blockade of receptor phosphorylation and interference with the Akt pathway. Of the chemotherapeutic agents tested in combination with imatinib, a synergistic effect was obtained with gemcitabine and pemetrexed. Conclusions: This study provides a rationale for a novel translational approach to the treatment of mesothelioma which relies on enhancement of tumour chemosensitivity by inhibition of Akt.

AB - Background: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet derived growth factor receptor β (PDGFRβ). PDGFRβ is often overexpressed in mesothelioma cells and is a therapeutic target for imatinib in some solid tumours. A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma. Methods: Cultures from mesothelioma MMP, REN ana ISTMES2 cell lines were treated with imatinib alone or in combination with a chemotherapeutic agent. Results: Imatinib induced cytotoxicity and apoptosis selectively on PDGFRp positive mesothelioma cells via blockade of receptor phosphorylation and interference with the Akt pathway. Of the chemotherapeutic agents tested in combination with imatinib, a synergistic effect was obtained with gemcitabine and pemetrexed. Conclusions: This study provides a rationale for a novel translational approach to the treatment of mesothelioma which relies on enhancement of tumour chemosensitivity by inhibition of Akt.

UR - http://www.scopus.com/inward/record.url?scp=34547765871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547765871&partnerID=8YFLogxK

U2 - 10.1136/thx.2006.069872

DO - 10.1136/thx.2006.069872

M3 - Article

C2 - 17311837

AN - SCOPUS:34547765871

VL - 62

SP - 690

EP - 695

JO - Thorax

JF - Thorax

SN - 0040-6376

IS - 8

ER -